Validation of a novel fluorescent lateral flow assay for rapid qualitative and quantitative assessment of total anti-SARS-CoV-2 S-RBD binding antibody units (BAU) from plasma or fingerstick whole-blood of COVID-19 vaccinees

Nadin Younes^{1,2,†}, Duaa W. Al-Sadeq^{1,3,†}, Farah M. Shurrah^{1,2, 1}, Hadeel T. Zidan^{1,2}, Haissam Abou-Saleh⁴, Bushra Y. Abo Halawa⁴, Fatima M. AlHamaydeh², Amira E. Elsharafi², Hanin I. Daas⁵, Swapna Thomas^{1,2}, Sahar Aboalmaal⁶, Afra Al Farsi⁶, Reeham Al-Buainain⁶, Samar Ataelmannan⁶, Jiji Paul⁶, Amana Salih Al Saadi⁶, Hadi M. Yassine^{1,2}, Amin F. Majdalawieh⁷, Ahmed Ismail⁶, Laith J. Abu-Raddad^{8,9,10}, Gheyath K. Nasrallah^{1,2,*}

¹ Biomedical Research Center, Qatar University, 2713 Doha, Qatar.

² Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, 2713 Doha, Qatar.

³ College of Medicine, Member of QU Health, Qatar University, 2713 Doha, Qatar.

⁴ Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University, 2713 Doha, Qatar.

⁵ College of Dental Medicine, QU Health, Qatar University, 2713 Doha, Qatar.

⁶ Laboratory Section, Medical Commission Department, Ministry of Public Health, 42 Doha, Qatar

⁷ Department of Biology, Chemistry and Environmental Sciences, College of Arts and Sciences, American University of Sharjah, 26666 Sharjah, United Arab Emirates.

⁸ Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation—Education City, 24144 Doha, Qatar

⁹ World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, 24144 Doha, Qatar

¹⁰ Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA

* **Correspond to:** Gheyath K. Nasrallah

Department of Biomedical Science, College of Health Sciences, Qatar University, Doha, Qatar

Women's Science building, C01, Tel: +974 4403 4817, Fax: +974-4403-1351, P.O. Box: 2713, email:

gheyath.nasrallah@qu.edu.qa.

1 Abstract

2 **Background:** Limited commercial LFA assays are available to provide a reliable quantitative
3 measurement of the total binding antibody units (BAU/mL) against the receptor-binding
4 domain of the SARS-CoV-2 spike protein (S-RBD). **Aim:** To evaluate the performance of
5 FinecareTM2019-nCoV S-RBD LFA and its fluorescent reader (FinecareTM-FIA Meter)
6 against the following reference methods (i) The FDA-approved Genscript surrogate virus-
7 neutralizing assay (sVNT), and (ii) three highly performing automated immunoassays:
8 BioMérieux VIDAS®3, Ortho VITROS®, and Mindray CL-900i®. **Methods:** Plasma from
9 488 vaccinees were tested by all aforementioned assays. Fingerstick whole-blood samples
10 from 156 vaccinees were also tested by FinecareTM. **Results and conclusions:** FinecareTM
11 showed 100% specificity as none of the pre-pandemic samples tested positive. Equivalent
12 FinecareTM results were observed among the samples taken from fingerstick or plasma
13 (Pearson correlation $r=0.9$, $p<0.0001$), suggesting that fingerstick samples are sufficient to
14 quantitate the S-RBD BAU/mL. A moderate correlation was observed between FinecareTM
15 and sVNT ($r=0.5$, $p<0.0001$), indicating that FinecareTM can be used for rapid prediction of
16 the neutralization antibody post-vaccination. FinecareTM BAU results showed strong
17 correlation with VIDAS®3 ($r=0.6$, $p<0.0001$), and moderate correlation with VITROS®
18 ($r=0.5$, $p<0.0001$), and CL-900i® ($r=0.4$, $p<0.0001$), suggesting that FinecareTM be used as
19 a surrogate for the advanced automated assays to measure S-RBD BAU/mL.

20

21 **Keywords:** SARS-CoV-2; COVID-19; Serology; Lateral Flow Assay; Automated
22 immunoassay; CLIA; Neutralizing antibodies; Surrogate virus neutralization test (sVNT).

23 **Introduction**

24 Serological immunoassays are rapidly emerging with varying degrees of sensitivity
 25 and specificity (1, 2). These include enzyme-linked immunosorbent assays (ELISAs),
 26 chemiluminescence assays (CLIA), electrofluorescent (ELFA), and lateral flow assays
 27 (LFAs). Most serological assays measure the binding antibodies (BA) response against
 28 specific SARS-CoV-2 antigens. Measuring binding antibodies is insufficient for assessing
 29 protective immunity since these antibodies (Abs) do not play significant roles in virus
 30 neutralization (3, 4). neutralizing antibodies (nAbs) are more indicative of protective
 31 immunity due to their ability not only to bind S-RBD, but also to block viral entry to the host
 32 cells (3, 5-8). Therefore, neutralization assays remain the gold standard for measuring the
 33 nAbs titer against SARS-CoV-2 (9). Nevertheless, nAb assays require high-level biosafety
 34 laboratories, highly trained personnel and often take several days to complete (9). To avoid
 35 such limitations, Genscript Biotech Corporation developed a reliable surrogate virus-
 36 neutralizing assay (known as sVNT or cPass) to measure the nAb. The cPass Genscript assay
 37 is now recommended by the World Health Organization (WHO) and also received the full
 38 USA FDA approval to be used as a reference assay for quantitative measurement of the nAb
 39 (10).

40 One of the major challenges for the commercially available serology assays is that
 41 their binding antibody results are provided in arbitrary units per milliliters (ARU/mL). Thus,
 42 the results between assays are highly variable, although they target the same SARS-CoV-2
 43 antigen, usually the S-protein. To minimize the discrepancies between serological assays, the
 44 WHO introduced an international standard to harmonize the antibodies immune response
 45 assessment and recommended reporting the assay results for binding activity in binding
 46 antibody unit per milliliter (BAU/mL) instead of arbitrary ARU/mL. (11). One of the best
 47 ways to identify a reliable assay that can be used as a surrogate assay to assess the quantity of

neutralizing Abs post-vaccination is by performing correlation studies between these assays and a reference neutralization assay.

LFAs are attractive for small or non-laboratory settings and population surveillance. They are affordable and rely on easily accessible specimens such as fingerstick whole blood, and provide the result within minutes. According to the literature, none of the few commercially available fluorescent LFAs that provide quantitative measurement of SARS-CoV-2 (in BAU/mL) to the S-RBD protein was validated. The FinecareTM2019-nCoV S-RBD Antibody Test is a fluorescence immunoassay used along FinecareTM FIA Meters (reader) (Model No.: FS-113) for quantitative detection of S-RBD BAU in human fingerstick whole blood, venipuncture whole blood, and serum or plasma specimens (12). For more information about the assay principle, see **Figure S1**. In this study, we aimed to evaluate the performance of FinecareTM2019-nCoV by comparing its results with (i) the Genescript a surrogate virus-neutralizing test (sVNT), and (ii) three highly performing commercially available automated anti-SARS-CoV-2 immunoassays; Mindray CL-900i[®] SARS-CoV-2 S-RBD IgG and BioMérieux VIDAS[®]3, which measure BAU for S-RBD (13, 14), and Ortho VITROS[®], which measures total BAU to the S1 spike protein subunit (13, 14).

2. Methods

2.1 Samples collection and ethical approval

Participants who received two BNT162b2 or mRNA-1273 vaccine doses were eligible for inclusion. A total of 488 EDTA whole-blood samples (5.0 mL) were collected between April and October 2021 from staff and students at Qatar University, the largest national university in Qatar. Plasma was separated from whole venous blood and stored at -80°C until performing the test. Demographic information and information on the previous infection with SARS-CoV-2 were collected through a self-administered questionnaire. Out of the total samples, 156 participants in the vaccinated group performed the FinecareTM test

with fingerstick whole blood. The study was reviewed and approved by the Institutional Review Board at Qatar University (QU-IRB 1537-FBA/21). All analyses were conducted according to the ethical standards of the Declaration of Helsinki of the World Medical Association (WMA).

77

78 **2.2 FincareFinecare™ anti-SARS-CoV-2 S-RBD total antibodies test**

79 **2.2.1 Fingerstick samples**

Briefly, the area of the fingertip was lanced with an alcohol pad. Then, the skin was punctured using a sterile lancet, and 20 µL of fingerstick blood was collected with the capillary sampler. The specimen was squeezed out into the detection buffer tube. After that, 75 µL of sample mixture was loaded into the sample well and was inserted into the Test Cartridge holder of Finecare™ FIA Meters. The reaction time is 15 minutes. The results unit is displayed as a relative fluorescence unit (RFU, AU/mL). To obtain the results in BAU/mL, the AU/mL values were multiplied by the WHO standard (20) that is provided by the manufacturer.

88 **2.2.2 Plasma samples**

According to the standard phlebotomy procedure, venipuncture whole blood specimens were collected from each participant in EDTA tubes. Then, plasma was separated from blood immediately, and the test was performed as described above in 2.2.1.

92 **2.3 Commercially available serological assays**

Samples were analyzed using three commercially available automated anti-SARS-CoV-2 immunoassays: Mindray CL-900i® SARS-CoV-2 IgG (Cat. No. SARS-CoV-2 S-RBD IgG122, Mindray, Shenzhen, China), VIDAS®3 SARS-CoV-2 IgG (Cat. No. 423834, BioMérieux, Marcy-l'Étoile, France), and Ortho VITROS® anti-SARS-CoV-2 total Ab (Ortho Clinical Diagnostics, USA). Each assay was performed according to the manufacturer's instructions. The characteristics of the assays, including detection method,

targeted antigens, sample volume, result interpretation, reported sensitivity and specificity, and WHO conversion factor to BAU/mL are summarized in **Table 1**.

Table 1. Characteristics of the automated analyzers used in this study.

Manufacturer	Automated Analyzer	Detection Method	Targeted Antigen	Sample Volume	Result Interpretation	Reported Sensitivity	Reported Specificity	WHO Conversion Factor	Reference
Mindray Bio-Medical Electronics Co., Ltd.	Mindray CL-900i® SARS-CoV-2 S-RBD IgG	CLIA *	S-RBD	10 µL (this volume does not include the dead volume)	<10 AU/mL: Negative ≥10 AU/mL: Positive	100% (≥15 days)	94.9%	1.15	(15, 16)
BioMérieux Diagnostics	VIDAS®3 SARS-CoV-2 IgG	ELFA *	S-RBD	100 µL (including the dead volume)	<1 AU/mL: Negative ≥1 AU/mL: Positive	100% (≥15 days)	98.5%	20.3	(17)
Ortho Clinical Diagnostics	Ortho VITROS® anti-SARS-CoV-2 Total Ab	CLIA	S (S1 subunit)	20 µL (this volume does not include the dead volume)	<1.0 S/C: Negative ≥1.0 S/C: Positive	NR	100%	17.8	(18)

NR: Not reported

*CLIA, Chemiluminescence Immunoassay; ELFA, Enzyme-Linked Fluorescent Assay; S: Spike Protein; N: Nucleocapsid Protein; S1: Subunit of the Spike Protein. NA: Not Applicable.

2.4 cPass Genscript sVNT

A SARS-CoV-2 surrogate virus neutralization test (sVNT) (Cat. No. L00847, GenScript Biotech, NJ, USA) was utilized as a reference test for detecting nAbs against SARS-CoV-2. The test was conducted following the manufacturer's specifications. Briefly, samples and controls (provided within the kit) were diluted 1:10 with the sample dilution buffer provided with the kit. Then, 125 μ L of sample/control was mixed in a 1:1 ratio with HRP-RBD solution and incubated at 37°C for 30 minutes. After that, 100 μ L of each sample/control was added to the hACE2 coated plate in duplicates. The plate was sealed and incubated for 15 minutes at 37°C. Wells were then washed 4x with 200 μ L of the wash solution provided. 100 μ L of the TMB solution was added per well and the plate was incubated in the dark for 15 minutes at room temperature. Finally, 50 μ L of stop solution was added to each well to quench the reaction, and absorbance was read at 450 nm. % inhibition of $\geq 30\%$ was considered positive, and percent inhibition of $< 30\%$ was considered negative. Conversion tool for cPass % inhibition to IU/mL of the WHO International Standard (NIBSC code 20/136) was calculated as established in this (10).

2.5 Statistical method

Correlation and linear regression analysis between Finecare™ and each commercial serological immunoassay and the sVNT were performed. Pearson correlation coefficient (r) was calculated. For absolute values of Pearson's r, 0–0.19 is denoted as very weak, 0.2–0.39 as weak, 0.40–0.59 as moderate, 0.6–0.79 as strong, and 0.8–1 as very strong correlation (19). Concordance analysis between Finecare™ and the three automated assays was conducted, which includes the overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA), accuracy/efficiency as well as Cohen's Kappa statistic. Cohen's Kappa measure is a robust metric that estimates the level of agreement between two diagnostic tests. A Kappa value < 0.40 denotes poor agreement, 0.40–0.59 denotes fair agreement, 0.60–0.74 denotes good agreement, and ≥ 0.75 denotes excellent agreement (20).

The significance level was indicated at 5%, and a 95% confidence interval (CI) was reported for each metric. All statistical analysis was performed using GraphPad Prism software (Version 8.2.1. San Diego, CA, USA).

3. Results

3.1. Finecare™ is a very specific and sensitive assay

To assess the specificity of the of the Finecare™, we tested 100 pre-pandemic plasma samples using Finecare™ as well as sVNT as a reference method. None of the tested samples were positive by any of the two assay, indicating 100% specificity of the Finecare™. Regarding the sensitivity, 156 plasma samples were tested by the sVNT and the Finecare™. 155 samples were positive by sVNT and Finecare™. However, only one sample tested negative with sVNT but positive with Finecare™ indicating 99.8% sensitivity of the Fincare™. Intrestingly this sample tested negative when fingerstick whole blood sample were tested. The discripancy between the reslts of plasma and fingerstick could be due to a technical error between the two different technichains who performed the test.

3.2. Finecare™ fingerstick and plasma results are comparable

We assessed the performance of Finecare™ using fingerstick whole blood samples. A total of 156 participants provided informed consent to receive a fingerstick and have venous blood drawn to generate matched plasma samples. These samples were tested using the Finecare™ and results were compared as shown in **Figure 1**. A very strong correlation was observed ($r=0.9$, $P<0.0001$) between fingerstick and venous plasma samples. Similarly, linear regression analysis showed that constructed model could strongly predict the dependent variable ($R^2=0.8$, $p<0.0001$). Most importantly, the interpretation concordance was 100%, demonstrating equivalency between fingerstick and venous plasma.

167

168

169

170

171 coefficient (r), coefficient of determination (R^2), and p -value are shown.

172

173 3.3 Moderate correlation between FinecareTM and sVNT

174 We evaluated the performance of FinecareTM in comparison to sVNT. Moderate

175 significant correlation between FinecareTM and sVNT with r -value of 0.5 ($p < 0.001$) was

176 shown in **Figure 2**. Most importantly, the interpretation concordance was 99.4% as only one

177 sample tested negative with sVNT but positive with FinecareTM.

3.4 Moderate to strong correlation between Finecare™ and three commercially available automated anti-SARS-CoV-2 immunoassays

The correlation and linear regression analysis between the readings obtained from Finecare™ and each automated immunoassay are illustrated in **Figure 3**. Pearson's correlation coefficients (r) showed a statistically significant positive correlation for Finecare™ with all three automated assays ($p<0.001$). The strongest correlation coefficient was shown with VIDAS®3 ($r=0.6$, **Figure 3A**), followed by VITROS® ($r=0.5$, **Figure 3C**), and CL-900i® ($r=0.4$, **Figure 3B**). Linear regression analysis showed that all constructed models could statistically significantly predict the dependent variable [Fine care (BAU/mL)]. The best regression model fitting the data was shown by VIDAS®3 ($R^2 = 0.3$), followed by VITROS® ($R^2 = 0.3$) and CL-900i® ($R^2 = 0.2$).

195

196

197

198

199

200

201 3.5. Excellent agreement between Finecare™ and the three automated anti-SARS-

202 CoV-2 immunoassays

203 The tests' agreements were studied in a pairwise fashion applying inter-rater
 204 agreement statistics; (Cohen's Kappa statistic, κ) (**Table 2**). The OPA, PPA, NPA were 100%
 205 between Finecare™ and the three automated immunoassays. In addition, Cohen's Kappa
 206 statistic denoted excellent agreement between Finecare™ and the three automated anti-
 207 SARS-CoV-2 immunoassays ($\kappa=1.00$). Most importantly, the interpretation concordance
 208 was 100%, demonstrating equivalency between Finecare™ and the three automated anti-
 209 SARS-CoV-2 immunoassays.

210

211

Table 2. Concordance assessment between Finecare™ and the three automated anti-SARS-CoV-2 immunoassays (CL-900i®, VIDAS®3, and VITROS®).

Test	Compared to	Overall Percent Agreement (OPA)	Positive Percent Agreement (PPA)	Negative Percent Agreement (NPA)	Accuracy/Efficiency	Cohen's Kappa Statistic
		% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	k (95% CI)
Finecare™	VIDAS®3	100 (98.90-100)	100 (98.90-100)	100 (2.5-100.00)	100 (98.90-100.00)	1.00 (0.40-0.86)
	CL-900i®	100 (99.25-100.00)	100 (99.25-100.00)	100 (15.81-100)	100 (99.25-100.00)	1.00 (0.52 to 0.96)
	VITROS®	100 (98.85-100)	100 (98.84-100)	100 (2.5-100.00)	100 (98.85-100.00)	1.00 (0.46-0.95)

4. Discussion

Despite this rapid progress in vaccines development, it is unlikely that COVID-19 will be eradicated in the near future. At best, COVID-19 infections can be brought under control to the point where life can return to "pre-COVID" normality (21). A key part of this approach will be the deployment of high throughput testing to determine who is immune and the duration of immune response (21). The rapid LFA-POC antibody tests are simple, cheap, and fast. They do not require qualified personnel for interpretation and could be done in non-laboratory settings. The usefulness of rapid tests for detection of SARS-CoV-2 Abs has been questioned regarding their inferiority compared to other serology assays. This is because none of the few commercially available LFAs provide quantitative measurement of SARS-CoV-2 (in BAU/mL) to the S-RBD. The Finecare™2019-nCoV S-RBD Antibody Test used along Finecare™ reader is the first quantitative LFA for the detection of S-RBD BAU in human fingerstick whole blood, venipuncture whole blood, and serum or plasma specimens

(12). WHO International Standard (BAU/mL) is essential for facilitating the standardization of SARS-CoV-2 serological methods and allow for comparison and harmonization of datasets across laboratories. This is critical for determining the antibody levels that are needed for efficacious vaccines and protection from emerging variants such as Omicron (22). Recent studies have shown that two-dose COVID-19 vaccine regimen do not induce enough neutralizing antibodies against the Omicron variant (22).

One of the major advantages of Finecare™ is using fingerstick whole blood samples and obtaining quantitative results within 15 minutes. Although Abs are more stable in serum/plasma samples, the whole blood samples are more convenient to use. Therefore, we assessed the performance of Finecare™ using fingerstick whole blood samples compared to venous plasma samples. A very strong correlation was observed ($r=0.9$, $P<0.0001$) between fingerstick and venous plasma samples. In addition, the interpretation concordance was 100%, demonstrating equivalency between fingerstick whole blood and venous plasma samples. Our results confirmed the feasibility of using fingerstick whole blood for SARS-CoV-2 IgG detection and showed excellent concordance with plasma values using Finecare™ assay. Collection of fingerstick whole blood samples in Microtainer tubes is quick and easy. It does not require a phlebotomist, making it an attractive alternative to venepuncture for use in SARS-CoV-2 drive-through testing sites. The simplicity of performing the LFA with whole blood also eliminates the need for centrifugation and plasma separation steps, reducing the cost and complexity of obtaining a result.

Finecare™, which targets S-RBD antibodies, showed a moderate degree of correlation ($r=0.5$, $p<0.001$) with the sVNT and demonstrated 100% specificity (data not shown). Most importantly, the interpretation concordance between Finecare™ and sVNT reached 99.4%. S-RBD plays an essential role in viral entry into the cells suggesting neutralizing properties and immunity against SARS-CoV-2 (5-8). Studies have shown that

serology assays that detect Abs against the S1 subunit or the RBD alone strongly correlate with neutralization activity (23-27). According to McAndrews et al., approximately 86% of individuals positive for S-RBD-binding Abs exhibited neutralizing capacity (3). Whereas Abs directed against the Nucleocapsid protein (NP) are only binding Abs with no neutralizing activity (3, 28).

The correlation and linear regression analysis between the readings obtained from Finecare™ and each automated anti-SARS-CoV-2 immunoassay was evaluated. Each assay was selected for previously determined performance (13, 14), ease-of-use characteristics (automated serology) and availability. Pearson's correlation coefficients (r) showed a statistically significant positive correlation between Finecare™ and all three automated assays ($p < 0.001$). The strongest correlation was shown with VIDAS®3 ($r=0.6$), followed by VITROS® ($r=0.5$), and CL-900i® ($r=0.4$). The best correlation with VIDAS®3 was expected as both assays are based on fluorescence immunoassay technology and solely target Abs against S-RBD. Cohen's Kappa statistic denoted excellent agreement between Finecare™ and the three automated anti-SARS-CoV-2 immunoassays. Interestingly, the interpretation concordance was 100%, demonstrating equivalency between Finecare™ and the three automated immunoassays. The excellent concordance between the POC Finecare™ and the automated serological assay makes it an attractive alternative for serological assays that do not require laboratory settings. The ability to rapidly, accurately, and affordably determine seroprevalence in a population will be an important tool in the growing arsenal of SARS-CoV-2 diagnostic testing and assessment of antibody response post-vaccination, particularly in resource-limited areas.

In conclusion, SARS-CoV-2 continues to spread and threatens to disrupt human activity for years to come. Fortunately, we already have vaccines that effectively reduce disease and are now being rolled out in many countries but countering that many countries have low vaccine

coverage and ongoing high rates of infection, raising the potential for immune-mediated selection escape variants. Finecare™ should contribute to more widespread access to immunity testing for many populations, including those in resource-poor areas with limited access to laboratories and equipment for more conventional virus neutralization tests or ELISA-based inhibition assays.

5. Author contributions

Conceptualization, GKN and LJA.; methodology, FMS, DWA, FMH, AES, BYH, ST, SAB, AA, RA, SA, JP, and AS; software, FMS, DWA, FMH, AES, BYH, SAB, AA, RA, SA, JP, and AS.; validation, FMS, DWA, FMH, AES, BYH, SAB, AA, RA, SA, JP, and AS.; formal analysis, GKN, FMS, HTZ, and NY investigation, GKN and LJA.; resources, GKN, LJA, and AA.; data curation, GKN, FMS, HTZ, and NY.; writing—original draft preparation, NY, DWA, and GKN; writing—review and editing, HID, HA, AFM and GKN.; visualization GKN, FMS, HTZ, and NY.; supervision, HA, AA, HMY, and GKN.; project administration, GKN and LJA.; funding, GKN, LJA, and AA. All authors have read and agreed to the published version of the manuscript.

6. Conflict of interest

GKN would like to declare that all test kits used in this study were provided as in-kind support for his lab to test seroprevalence of anti-SARS-CoV-2 and antibody response among vaccinated and infected individuals in Qatar.

7. Funding:

This work was made possible by grant number UREP28-1733- 057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.

8. Ethical approval:

305 The study was reviewed and approved by the Institutional Review Board at Qatar
306 University (QU-IRB 1537-FBA/21). All analyses were conducted according to the ethical
307 standards of the Declaration of Helsinki of the World Medical Association (WMA).
308
309

9. References

1. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, et al. Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. *J Infect Dis.* 2020;222(8):1280-8.
2. Younes N, Al-Sadeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, et al. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. *Viruses.* 2020;12(6).
3. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. *JCI Insight.* 2020;5(18).
4. Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. *Nature Communications.* 2021;12(1):2670.
5. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol.* 2020;5(48).
6. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. *Clin Infect Dis.* 2020;71(16):2027-34.
7. Traugott M, Aberle SW, Aberle JH, Griebler H, Karolyi M, Pawelka E, et al. Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-Linked Immunosorbent Assays and Rapid Tests. *J Infect Dis.* 2020;222(3):362-6.
8. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. *Emerg Infect Dis.* 2020;26(7):1478-88.
9. Khoury DS, Wheatley AK, Ramuta MD, Reynaldi A, Cromer D, Subbarao K, et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. *Nature Reviews Immunology.* 2020;20(12):727-38.
10. Zhu F, Althaus T, Tan CW, Costantini A, Chia WN, Van Vinh Chau N, et al. WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. *The Lancet Microbe.*
11. Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, et al. WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. *The Lancet Microbe.*
12. Wondfo. Finecare 2019-nCoV RBD Antibody Test 2021 [Available from: https://www.finecare.it/wp-content/uploads/2021/04/W290_RBD_Antibody_Binder.pdf].
13. Younes S, Al-Jighefee H, Shurab F, Al-Sadeq DW, Younes N, Dargham SR, et al. Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-CoV-2 Individuals. *Microorganisms.* 2021;9(2).
14. Ismail A, Shurab FM, Al-Jighefee HT, Al-Sadeq DW, Qotba H, Al-Shaar IA, et al. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays. *Front Biosci (Landmark Ed).* 2021;26(7):198-206.
15. Nuccetelli M, Pieri M, Grelli S, Ciotti M, Miano R, Andreoni M, et al. SARS-CoV-2 infection serology: a useful tool to overcome lockdown? *Cell Death Discov.* 2020;6:38-.
16. IgG(CLIA) ICM-C-MS-C-. 2020 [Available from: <https://www.mindray.com/en/product/CL-900i.html>].

359 17. BIOMÉRIEUX. VIDAS® SARS-COV-2 2020 [Available from:
360 <https://www.biomerieux-diagnostics.com/vidas-sars-cov-2>
361 18. VIPA-S-C-TRP-If U. VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total
362 Reagent Pack—Instructions for Use. 2021 [Available from:
363 <https://www.fda.gov/media/136967/download>.
364 19. Miot HA. Correlation analysis in clinical and experimental studies. *J Vasc Bras*.
365 2018;17(4):275-9.
366 20. Kirch W. Kappa coefficient. In *Encyclopedia of Public Health*. Springer: Dordrecht,
367 The Netherlands. 2008:821–2.
368 21. Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, et al. A point-
369 of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. *EBioMedicine*.
370 2021;74:103729.
371 22. Lu L, Mok BW, Chen LL, Chan JM, Tsang OT, Lam BH, et al. Neutralization of
372 SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.
373 *Clin Infect Dis*. 2021.
374 23. Tan CW, Chia WN, Qin X, Liu P, Chen MIC, Tiu C, et al. A SARS-CoV-2 surrogate
375 virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–
376 protein interaction. *Nature Biotechnology*. 2020;38(9):1073-8.
377 24. Valcourt EJ, Manguiat K, Robinson A, Chen JC, Dimitrova K, Philipson C, et al.
378 Evaluation of a commercially-available surrogate virus neutralization test for severe acute
379 respiratory syndrome coronavirus-2 (SARS-CoV-2). *Diagn Microbiol Infect Dis*.
380 2021;99(4):115294.
381 25. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al.
382 Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological
383 Assays. *Clin Chem*. 2020;66(12):1538-47.
384 26. Hörber S, Soldo J, Relker L, Jürgens S, Guthier J, Peter S, et al. Evaluation of three
385 fully-automated SARS-CoV-2 antibody assays. *Clin Chem Lab Med*. 2020;58(12):2113-20.
386 27. Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, et al.
387 Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. *bioRxiv* :
388 the preprint server for biology. 2020:2020.05.12.091298.
389 28. Rump A, Risti R, Kristal M-L, Reut J, Syritski V, Lookene A, et al. Dual ELISA
390 using SARS-CoV-2 nucleocapsid protein produced in *E. coli* and CHO cells reveals epitope
391 masking by N-glycosylation. *Biochem Biophys Res Commun*. 2021;534:457-60.
392

Figure S1 overview of Finecare™2019-nCoV S-RBD lateral flow assay principle.